Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology

Journal of Psychopharmacology

Volumn 25, Issue 8, 2011, Pages 997-1019

  O'Brien, John T ^a   Burns, Alistair ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer's disease; dementia; guidelines; treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID PROTEIN; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DEXAMPHETAMINE; DIMEBON; DONEPEZIL; ESTROGEN; FOLIC ACID; GALANTAMINE; GESTAGEN; GINKGO BILOBA EXTRACT; HUPERZINE A; IDAZOXAN; LEVODOPA; MEMANTINE; MEPACRINE; METHYLPHENIDATE; NIMODIPINE; NOOTROPIC AGENT; PAROXETINE; PENTOSAN POLYSULFATE; PLACEBO; RIVASTIGMINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TACRINE; TAU PROTEIN; TRAZODONE; UNINDEXED DRUG;

AGITATION; ALZHEIMER DISEASE; BREAST CARCINOMA; CADASIL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CORTICOBASAL DEGENERATION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRONTOTEMPORAL DEMENTIA; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROIMAGING; PARKINSON DISEASE DEMENTIA; POSTMENOPAUSE; PRIMARY MEDICAL CARE; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SIDE EFFECT; STROKE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LEWY BODY DISEASE; MEMANTINE;

EID: 80051957021     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110387547     Document Type: Review

References (148)

1. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies; a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 ; 8: 613-618
2. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry. 2002 ; 72: 708-712 (Pubitemid 34557010)
3. Aarsland D, Rongve A, Nore SP, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008 ; 26: 445-452
4. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with ionophoric activity. Neuron. 2008 ; 59: 43-55 (Pubitemid 351905863)
5. Ahmad S, Orrell M, Iliffe S and Gracie A (2010) GPs' attitudes, awareness, and practice regarding early diagnosis of dementia. Br J Gen Pract 60(578): 360-365.
6. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 ; 300 (15). 1774-1783
7. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008 ; 65: 1509-1517
8. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Arlington, VA: American Psychiatric Publishing Inc ; 1994 :
9. DSMIII. Arlington, VA: American Psychiatric Publishing Inc ; 2000 :
10. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008 ; 22: 343-396 (Pubitemid 351989984)
11. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1994 ; 154: 2154-2160 (Pubitemid 24317261)
12. Ashley PJS Oxford Textbook of Old Age Psychiatry. Jacoby R Oppenheimer C Dening T Thomas A, ed. Oxford: Oxford University Press ; 2009 :
13. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007 ; 69: 448-458 (Pubitemid 47450280)
14. Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008 ; 24: 2561-2574
15. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000 ; 6: 916-919 (Pubitemid 30644751)
16. Baskys A and Hou AC (2007) Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2(3): 327-335.
17. Beckett N, Peters R, Fletcher A, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 ; 358: 1887-1898 (Pubitemid 351620109)
18. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 ; 132: 156-171
19. Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in Dementia with Lewy Bodies-which one to use?. Int J Geriatr Psychiatry. 2007 ; 22: 890-895 (Pubitemid 47455272)
20. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev Art. No.: CD006104, DOI: 10.1002/14651858. 2009 ;:
21. Birks J and Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev Art. No.: CD003120, DOI: 10.1002/14651858.
22. Bocti C, Black S, Frank C. Management of dementia with a cerebrovascular component. Alzheimers Dement. 2007 ; 3: 398-403 (Pubitemid 47541949)
23. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004 ; 63: 376-378 (Pubitemid 38971150)
24. Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009 ; 23: 211-217
25. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006 ; 20: 732-755 (Pubitemid 44622739)
26. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009 ; 132: 195-203
27. Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging. 2005 ; 22 (Suppl 1). 1-26 (Pubitemid 41565869)
28. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009 ; 8: 334-344
29. Colloby SJ, Firbank MJ, Pakrasi S, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatrics. 2008 ; 20: 1124-1140
30. Cooper C, Blanchard M, Selwood A, Livingston G. Antidementia drugs: prescription by level of cognitive impairment or by socio-economic group?. Aging Ment Health. 2010 ; 14: 85-89
31. Coull JT, Sahakian BJ, Hodges JR. The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology. 1996 ; 123: 239-249 (Pubitemid 26072837)
32. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004 ; 172: 400-408 (Pubitemid 38650975)
33. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008 ; 300: 2253-2262
34. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009 ; 73: 674-680
35. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008 ; 7: 310-318
36. Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008 ; 23: 754-759
37. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004 ; 75: 1472-1474 (Pubitemid 39279821)
38. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 2008 ; 70 (19 Pt 2). 1809-1817 (Pubitemid 351653954)
39. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 ; 372 (9634). 207-215 (Pubitemid 351978110)
40. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 ; 6: 734-746 (Pubitemid 47058377)
41. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double-blind, controlled trial. [see comment]. Lancet. 2007 ; 369 (9557). 208-216 (Pubitemid 46107683)
42. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New Eng J Med. 2004 ; 351: 2509-2518 (Pubitemid 39603164)
43. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 ; 22: 1689-1707 (Pubitemid 47597592)
44. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001 ; 103: 123-125 (Pubitemid 32113107)
45. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 ; 57: 613-620 (Pubitemid 32782987)
46. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev Art. No. CD001011, DOI: 10.1002/14651858. 2001 ;:
47. Forette F, Seux M-L, Staessen J, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (syst-Eur) trial. Lancet. 1998 ; 352: 1347-1351 (Pubitemid 28510916)
48. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 ; 23: 537-545 (Pubitemid 351722115)
49. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's Disease: The Disability Assessment for Dementia. Am J Occup Therapy. 1999 ; 53: 471-481
50. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 ; 64: 1553-1562 (Pubitemid 40617691)
51. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 ; 23: 2248-2250
52. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001 ; 13: 199-205 (Pubitemid 32703331)
53. Green RC, Schneider LS, Amato DA, et al. Effect of Tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer's disease. A randomized controlled trial. JAMA. 2009 ; 302: 2557-2564
54. Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer's disease: a randomised, single blind, placebo controlled, multicenter 10-week study. J Clin Psychiatry. 2009 ; 70: 922-931
55. Hao Z, Liu M, Liu Z, Lv D. Huperzine A for vascular dementia. Cochrane Database Syst Rev. 2009 ;:
56. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003 ; 38: 547-554 (Pubitemid 36645030)
57. Hogervorst E, Yaffe K, Richards M, Huppert FAH. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009 ;:
58. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 ; 372 (9634). 216-223 (Pubitemid 351978111)
59. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010 ; 17 (10). 1236-1248
60. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. New Eng J Med. 2007 ; 357: 1382-1392 (Pubitemid 47535593)
61. Huey ED, Garcia C, Wassermann EM, Tierney MC, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008 ; 69: 1981-1982
62. Johnell K, Weitoft GR, Fastbom J. Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord. 2008 ; 25: 54-59 (Pubitemid 350308387)
63. Jorm AF, Dear KB, Burgess NM. Projections of future numbers of dementia cases in Australia with and without prevention. Aust N Z J Psychiatry. 2005 ; 39: 959-963 (Pubitemid 43904431)
64. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 ; 6: 782-792 (Pubitemid 47243710)
65. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Anti-hypertensive medication use and incident Alzheimer's disease. The Cache County Study. Arch Neurol. 2006 ; 63: 686-692
66. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56: 1143-1153 (Pubitemid 32405708)
67. Lannfelt L, Blennow K, Zetterberg H, et al. Targeting Aβ as a modifying therapy of Alzheimer's disease: safety, efficacy and biomarker findings of a Phase IIa Randomised, Double-Blind Placebo-Controlled trial of PBT2. Lancet Neurol. 2008 ; 7: 779-786
68. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004 ; 17: 355-359 (Pubitemid 38721158)
69. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008 ;:
70. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001 ; 57: 467-473 (Pubitemid 32757595)
71. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 ; 18: 467-486 (Pubitemid 36656531)
72. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 ; 80: 600-607
73. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002 ;:
74. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database System Rev. 2006 ;:
75. Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 2009 ; 72: 2115-2121
76. McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2008 ; 23: 1222-1230
77. MacDonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry. 2008 ; 23: 704-711
78. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003 ;:
79. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008 ;:
80. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004 ;:
81. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009 ; 302: 385-393
82. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol. 2006 ; 13: 981-985 (Pubitemid 44284905)
83. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009 ;:
84. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000 ; 356: 2031-2036 (Pubitemid 32009817)
85. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005 ; 65: 1863-1872 (Pubitemid 43970103)
86. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 ; 47: 1113-1124 (Pubitemid 26374873)
87. McKeith I, Mintzer J, Aarsland D, et al. International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 2004 ; 3: 19-28
88. McKeith IG, Rowan E, Askew K, et al. More severe functional impairment in dementia with Lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry. 2006 ; 14: 582-588 (Pubitemid 44036482)
89. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007 ; 6: 305-313 (Pubitemid 46367938)
90. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34: 939-944 (Pubitemid 14076461)
91. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 ;:
92. Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009 ; 24: 532-538
93. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007 ; 15: 84-87 (Pubitemid 46106094)
94. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med. 2000 ; 19: 1607-1616 (Pubitemid 30346250)
95. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007 ; 69: 1850-1858 (Pubitemid 350071146)
96. Minett TSC, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open-label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003 ; 18: 988-993 (Pubitemid 37479370)
97. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry. 2009 ; 80: 966-975
98. Molloy S, McKeith I, O'Brien JT, Burn D. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 ; 76: 1200-1203 (Pubitemid 41208368)
99. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003 ; 49: 13-19 (Pubitemid 35477963)
100. Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia. Am J Alzheimers Dis Other Demen. 2008 ; 23: 167-176 (Pubitemid 351550908)
101. Napryeyenko O, Borzenko I. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007 ; 57: 4-11 (Pubitemid 46212982)
102. Dementia: Supporting people with dementia and their carers in health and social care. London: NICE ; 2006 :
103. Nicoll JA, Barton E, Boche D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006 ; 65: 1040-1048 (Pubitemid 44684661)
104. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003 ; 9: 448-452 (Pubitemid 36460079)
105. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiology. 2007 ; 80 (Spec No 2). S71-77
106. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol. 2003 ; 2: 89-98 (Pubitemid 37443329)
107. O'Brien JT, McKeith IG, Walker Z, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry. 2009 ; 194: 34-39
108. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009 ; 73: 754-760
109. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003 ; 61: 46-54 (Pubitemid 36818745)
110. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005 ; 36: 619-624 (Pubitemid 40344166)
111. Passmore AP, Bayer AJ, Steinhagen-Thiessen E. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci. 2005 ; 229-230: 141-146 (Pubitemid 40341577)
112. Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C. Absence of cholinergic deficits in "pure" vascular dementia. Neurology. 2005 ; 64: 132-133 (Pubitemid 40082950)
113. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering, the results of the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG). A double-blind, placebo controlled trial. Lancet Neurol. 2008 ; 7: 683-689
114. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 ; 5: 83-89 (Pubitemid 351536358)
115. Purandare N, Ballard C, Burns A Dementia (3rd Edition). Burns A O'Brien J Ames D, ed. London: Edward Arnold ; 2005: 515-521.
116. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006 ; 31: 651-658 (Pubitemid 43276981)
117. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 ; 30: 1728-1736
118. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA. Evaluation of vascular care in Alzheimer's disease. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009 ; 57: 797-805
119. Rockwood K, Middleton LE, Moorhouse PK, Skoog I, Black SE. The inclusion of cognition in vascular risk factor clinical practice guidelines. Clin Interv Aging. 2009 ; 4: 425-433
120. Rojas-Fernandez CH and Moorhouse P (2009) Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother 43(7): 1310-1323.
121. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993 ; 43: 250-260 (Pubitemid 23060253)
122. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007 ; 68: 1718-1725 (Pubitemid 46763260)
123. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 ; 73: 2061-2070
124. Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000 ; 15: 794-802
125. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999 ; 400 (6740). 173-177 (Pubitemid 29327547)
126. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005 ; 2: 541-551 (Pubitemid 41703672)
127. Sharp SI, Francis PT, Elliott MS, et al. Choline acetyltransferase activity in vascular dementia and stroke. Dement Geriatr Cogn Disord. 2009 ; 28: 233-238
128. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004 ; 291 (24). 2947-2958 (Pubitemid 38802684)
129. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.[see comment]. JAMA. 2003 ; 289 (20). 2651-2662 (Pubitemid 37430136)
130. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE)-a randomized double-blind trial. Am J Hypertens. 2005 ; 18: 1052-1059 (Pubitemid 41139903)
131. Skoog I, Gustafson D Trial Designs and Outcomes in Dementia Therapeutic Research. Rockwood K Gauthier S, ed. Abingdon: Taylor & Francis ; 2006: 189-211.
132. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008 ; 23: 942-949
133. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007 ; 21: 164-166 (Pubitemid 46878979)
134. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 ; 291: 317-324 (Pubitemid 38101604)
135. Thaisetthawatkul P, Boeve BF, Benarroch EE, et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology. 2004 ; 62: 1804-1809 (Pubitemid 38661739)
136. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging. 2009 ; 4: 367-377
137. Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology. 2009 ; 29: 632-636
138. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003 ; 163: 1069-1075 (Pubitemid 36548935)
139. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med. 2006 ; 145: 713-726 (Pubitemid 351650351)
140. Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol. 2008 ; 21: 708-716
141. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007 ; 14: e1-26
142. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008 ; 7: 483-493
143. Wilcock GK, Black SE, Balch AH, et al. (2009) Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial. International Conference on Alzheimer's Disease: Vienna.
144. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007 ; 24: 138-145 (Pubitemid 47094073)
145. Wilkinson D, Schindler R, Schwam E, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2009 ; 28: 244-251
146. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 ; 57: 489-495 (Pubitemid 32757598)
147. Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. 2009 ; 13: 183-190
148. Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006 ; 66: 1850-1854 (Pubitemid 44049815)